The CMV Resistance measures: Maribavir, Letermovir, Ganciclovir, Foscarnet, Cidofovir Human Cytomegalovirus (CMV) infections are a major cause of morbidity and mortality among immunocompromised patients.
Specimen Sources
Blood, ArterialBlood, CapillaryBlood, Central LineBlood, Venous
Specimen Types
Blood
Specimen Volume
Container
Lavender Top Tube
Collection Instructions
Container/Tube: Lavender (EDTA) Top Tube Specimen: 2 mL plasma (0.2 mL min) Samples must be received within 6 days of collection unless frozen
Transport Instructions
Refrigerated
Specimen Stability
7 Days room Temperature 7 Days Refrigerated 60 Days Frozen
Methodology
PCR followed by genotypic sequencing
Days Performed
TAT: 3 - 5 Days Patient outcomes depend on effective prophylaxis and treatment with antiviral therapies, including maribavir, letermovir, cidofovir, ganciclovir, valganciclovir and foscarnet. Additionally, letermovir is approved specifically for prophylactic use in hematopoietic stem cell transplant (HSCT) patients. Proper patient management requires rapid detection of resistance. Laboratory testing should be used to confirm the occurrence of drug resistance, as treatment modification based solely on clinical suspicion may result in added toxicity and increased complexity in patient management. The CMV Resistance: Maribavir, Letermovir, Ganciclovir, Foscarnet, Cidofovir sequencing assay is designed to detect identified mutations in the UL54, UL56 and UL97 genes of CMV. The use of genotypic sequencing offers a rapid turnaround time, a broad range of antiviral resistance information, and the ability to provide information concerning new drugs as they become available
Performing Laboratories
Eurofins-Viracor
CPT
87910 x 3
PDM
235701
Results
Component Name
Base Name
Common Name
External Name
MARIBAVIR UL97
MARIBAV
MARIBAVIR UL97
Maribavir UL97
GANCICLOVIR UL97
GANC97
GANCICLOVIR UL97
Ganciclovir UL97
GANCICLOVIR UL54
GANC54
GANCICLOVIR UL54
Ganciclovir UL54
CIDOFOVIR UL54
CIDOFOVIR
CIDOFOVIR UL54
Cidofovir UL54
FOSCARNET UL54
FOSCARNET
FOSCARNET UL54
Foscarnet UL54
LETERMOVIR UL56
LETERUL56
LETERMOVIR UL56
Letermovir UL56
Result Interpretation
Mutations in the UL54, UL56 and UL97 genes will be reported as
Resistant/None Detected. Interpretation of gene mutations and
association with antiviral resistance, including maribavir, ganciclovir,
foscarnet, and cidofovir and letermovir will be provided with the report
Specificity
CMV sequencing analysis provides information about selected
locations in three genes, UL54, UL56, and UL97 involved in CMV antiviral resistance.
